A silent liver disease epidemic
As nonalcoholic steatohepatitis, or NASH, stealthily becomes a leading cause of liver transplants, drug companies are racing to develop treatments
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
October 3, 2016 Cover
Volume 94, Issue 39
As nonalcoholic steatohepatitis, or NASH, stealthily becomes a leading cause of liver transplants, drug companies are racing to develop treatments
Cover image:
Credit:
Drug Development
Has lignin’s time finally come?
After years of burning it, companies are starting to recover the ubiquitous tree biopolymer
Taking catalysis to the atomic limit
Chemists advance single-atom supported catalysts from farfetched idea to reality
-
Engineers work to improve that electric feel
Advances in electronic skin could lead to better prosthetics and more independent robots
-
Perspectives: Nonprofit groups come in many colors
A veteran chemist lays out the challenges and benefits of working for one of today’s nonprofit environmental organizations
-
Rx-360 comes of age
Built to ensure quality of raw materials, consortium still struggles to sign on generic drugmakers
ADVERTISEMENT
Science Concentrates
Cooking up the ultimate sweetener
Manus Biosynthesis has developed a scalable fermentation process to make rebaudioside M, a highly sought zero-calorie sugar substitute
